findmyKOL

John Weiter, MD, PhD

Basic profile

Massachusetts Eye and Ear Infirmary

ORCIDNone on fileNPI
RegionPeabody, MA · NortheastSpecialtyOphthalmologyFocusOphthalmology
Last active 2023findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2004Online presenceNot yet checkedPayments2021 onwardNIH funding1985–1987Why? →

John Weiter is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 164 publications with 8,344 citations (h-index 39). By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
164publications

Distinct works indexed by OpenAlex.

8,344citations

Total citations across indexed works.

39h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 1985–1987

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

39 Cross St Ste 201
Peabody, MA 019601666

Telephone

978-854-5090

Provider last certified this registry record 9 Apr 2024.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    56.4%
    Vascular Endothelial Growth Factor Inhibitor56.4%
    Bevacizumab100%
    Part B, office-administered16 patients
  • Sensory organs

    43.6%
    Prostaglandin Analog43.6%
    Latanoprost100%
    Part D17 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 19851987 per NIH RePORTER. The latest:

1 more award record behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

45 more publications behind the reveal.Reveal →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”